Atopic gastritis is chronic inflammation of gastric mucosa, and it is a histopathological condition associated with gastric glandular cell and replacement by fibrous tissue, intestinal type epithelium, and pyloric type glands. It mainly associatedÊH. PyloriÊbacterial infection, and autoimmunity directed against gastric glandular cell. Symptoms include stomach pain, loss of appetite, nausea, unexpected weight loss, iron deficiency anemia. There is a high chance for the development of pernicious anemia in autoimmune atrophic gastritis Individual due to the loss of anti-intrinsic antibodies and parietal cell mass. Atrophic gastritis associated withÊH. PyloriÊare at high risk of developing gastric carcinoma and is frequently asymptomatic. Individuals associated with chronic atrophic gastritis develop hypergastrinemia and low gastric acid output which may lead to carcinoid tumors and enterochromaffin-like cell hyperplasia. Atrophic gastritis develops at childhood and if, it is left untreated atrophic gastritis progress throughout the lifespan.Ê Treatment mainly includes antibiotics for eliminatingÊH. PyloriÊbacteria. Symptomatic treatment includes vitamin B-12 injections. Proton pump inhibitors used to control the acidity of the stomach.Ê Autoimmune atrophic gastritis associated with gastric polyps, pernicious anemia, and adenocarcinoma. Atrophic gastritis diagnosed by low levels of B-12, low levels of pepsinogen, high levels of gastrin and intrinsic factors.
Scope of the Report:This report studies the Atrophic Gastritis Treatment market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Atrophic Gastritis Treatment market by product type and applications/end industries.
Atrophic gastritis is associated with loss of gastric gland and is a progressive condition with the replacement of metaplasia. It is asymptomatic and associated with large complications like gastric carcinoma, hyperplasia, hypergastrinemia, increased risk of heart attack in elderly. The frequency of atrophic gastritis is unknown due to it is mostly asymptomatic. Atrophic gastritis is extremely common and is highly prevalent in different parts of the globe. In atrophic gastritis, eradication ofÊH. Pylori is highly complicated, and it requires follow-up for several years. Eradication ofÊH. PyloriÊreduces the risk of developing cancers in late stages. Mortality and morbidity associated with atrophic gastritis are depended on underlying complications of diseases. Atrophic gastritis requires a continuous management because recurrence of illness is high.Ê All these factors act as a driver in the robust growth of the atrophic gastritis treatment market.
The global Atrophic Gastritis Treatment market is valued at xx million USD in 2020 and is expected to reach xx million USD by the end of 2026, growing at a CAGR of xx% between 2020 and 2026.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Atrophic Gastritis Treatment.
Europe also play important roles in global market, with market size of xx million USD in 2020 and will be xx million USD in 2026, with a CAGR of xx%.
Market Segment by Companies, this report covers Takeda Pharmaceutical Company Limited
PERNIX Therapeutics
Perrigo Pharmaceutical
Teva Pharmaceutical
Market Segment by Regions, regional analysis covers North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers Coating Agents
Antibiotics
Vitamin B-12
Market Segment by Applications, can be divided into Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies
Frequently Asked Questions
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
- By Type
- By Application
- By Region
- By Country
- By Manufacturer
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
